Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 390

1.

Impact of biopsy perineural invasion on the outcomes of patients who underwent radical prostatectomy: a systematic review and meta-analysis.

Wu S, Lin X, Lin SX, Lu M, Deng T, Wang Z, Olumi AF, Dahl DM, Wang D, Blute ML, Wu CL.

Scand J Urol. 2019 Aug 10:1-8. doi: 10.1080/21681805.2019.1643913. [Epub ahead of print]

PMID:
31401922
2.

Re: Active Surveillance of Prostate Cancer is a Viable Option for Men Younger than 60 Years.

Salari K, Kuppermann D, Preston MA, Dahl DM, Barrisford GW, Efstathiou JA, Blute ML, Vesprini D, Loblaw A, Zietman AL, Klotz L, Feldman AS.

J Urol. 2019 Jun 4:101097JU0000000000000363. doi: 10.1097/JU.0000000000000363. [Epub ahead of print] No abstract available.

PMID:
31163004
3.

Management of Local Kidney Cancer Relapse.

Zlatev DV, Blute ML.

Eur Urol Oncol. 2018 Dec;1(6):524. doi: 10.1016/j.euo.2018.10.009. Epub 2018 Nov 22. No abstract available.

PMID:
31158098
4.

Multiparametric Magnetic Resonance Imaging-Ultrasound Fusion Biopsy Improves But Does Not Replace Standard Template Biopsy for the Detection of Prostate Cancer.

Hanna N, Wszolek MF, Mojtahed A, Nicaise E, Wu B, Gelpi-Hammerschmidt FJ, Salari K, Dahl DM, Blute ML, Harisinghani M, Feldman AS.

J Urol. 2019 May 30:101097JU0000000000000359. doi: 10.1097/JU.0000000000000359. [Epub ahead of print]

PMID:
31144593
5.

Individualised Indications for Cytoreductive Nephrectomy: Which Criteria Define the Optimal Candidates?

Larcher A, Wallis CJD, Bex A, Blute ML, Ficarra V, Mejean A, Karam JA, Van Poppel H, Pal SK.

Eur Urol Oncol. 2019 Jul;2(4):365-378. doi: 10.1016/j.euo.2019.04.007. Epub 2019 May 18. Review.

PMID:
31109902
6.

Active Surveillance of Prostate Cancer is a Viable Option for Men Younger than 60 Years.

Salari K, Kuppermann D, Preston MA, Dahl DM, Barrisford GW, Efstathiou JA, Blute ML, Vesprini D, Loblaw A, Zietman AL, Klotz L, Feldman AS.

J Urol. 2019 Apr;201(4):721-727. doi: 10.1097/JU.0000000000000031.

PMID:
30664083
7.

Type 2 Diabetes in Relation to the Risk of Renal Cell Carcinoma Among Men and Women in Two Large Prospective Cohort Studies.

Graff RE, Sanchez A, Tobias DK, Rodríguez D, Barrisford GW, Blute ML, Li Y, Sun Q, Preston MA, Wilson KM, Cho E.

Diabetes Care. 2018 Jul;41(7):1432-1437. doi: 10.2337/dc17-2518. Epub 2018 Apr 20.

8.

Loss of Igf2 Gene Imprinting in Murine Prostate Promotes Widespread Neoplastic Growth.

Damaschke NA, Yang B, Bhusari S, Avilla M, Zhong W, Blute ML Jr, Huang W, Jarrard DF.

Cancer Res. 2017 Oct 1;77(19):5236-5247. doi: 10.1158/0008-5472.CAN-16-3089. Epub 2017 Aug 3.

9.

Delayed Intervention of Small Renal Masses on Active Surveillance.

Gupta M, Blute ML Jr, Su LM, Crispen PL.

J Kidney Cancer VHL. 2017 May 24;4(2):24-30. doi: 10.15586/jkcvhl.2017.75. eCollection 2017.

10.

Patient-reported Functional Outcomes Following Open, Laparoscopic, and Robotic Assisted Radical Prostatectomy Performed by High-volume Surgeons at High-volume Hospitals.

Gershman B, Psutka SP, McGovern FJ, Dahl DM, Tabatabaei S, Gettman MT, Frank I, Carlson RE, Rangel LJ, Barry MJ, Blute ML, Karnes RJ.

Eur Urol Focus. 2016 Jun;2(2):172-179. doi: 10.1016/j.euf.2015.06.011. Epub 2015 Jul 15.

PMID:
28723533
11.

Reduced estimated glomerular filtration rate (eGFR <60 mL/min/1.73 m2 ) at first transurethral resection of bladder tumour is a significant predictor of subsequent recurrence and progression.

Blute ML Jr, Kucherov V, Rushmer TJ, Damodaran S, Shi F, Abel EJ, Jarrard DF, Richards KA, Messing EM, Downs TM.

BJU Int. 2017 Sep;120(3):387-393. doi: 10.1111/bju.13904. Epub 2017 Jun 23.

12.

Lymph Node Dissection for Small Renal Masses.

Blute ML Jr, Gupta M, Crispen PL.

Urol Clin North Am. 2017 May;44(2):269-274. doi: 10.1016/j.ucl.2016.12.012. Epub 2017 Mar 14. Review.

PMID:
28411918
13.

Predictive Nomogram for Recurrence following Surgery for Nonmetastatic Renal Cell Cancer with Tumor Thrombus.

Abel EJ, Masterson TA, Karam JA, Master VA, Margulis V, Hutchinson R, Lorentz CA, Bloom E, Bauman TM, Wood CG, Blute ML Jr.

J Urol. 2017 Oct;198(4):810-816. doi: 10.1016/j.juro.2017.04.066. Epub 2017 Apr 12.

14.

Persistence of senescent prostate cancer cells following prolonged neoadjuvant androgen deprivation therapy.

Blute ML Jr, Damaschke N, Wagner J, Yang B, Gleave M, Fazli L, Shi F, Abel EJ, Downs TM, Huang W, Jarrard DF.

PLoS One. 2017 Feb 24;12(2):e0172048. doi: 10.1371/journal.pone.0172048. eCollection 2017.

15.

Case 5-2017. A 19-Year-Old Man with Hematuria and a Retroperitoneal Mass.

Blute ML Sr, Abramson JS, Cronin KC, Nardi V.

N Engl J Med. 2017 Feb 16;376(7):684-692. doi: 10.1056/NEJMcpc1610100. No abstract available.

PMID:
28199810
16.

Clinical Outcomes of Patients with Histologic Variants of Urothelial Cancer Treated with Trimodality Bladder-sparing Therapy.

Krasnow RE, Drumm M, Roberts HJ, Niemierko A, Wu CL, Wu S, Zhang J, Heney NM, Wszolek MF, Blute ML, Feldman AS, Lee RJ, Zietman AL, Shipley WU, Efstathiou JA.

Eur Urol. 2017 Jul;72(1):54-60. doi: 10.1016/j.eururo.2016.12.002. Epub 2016 Dec 28.

PMID:
28040351
17.

Metastatic Tumor Burden Does Not Predict Overall Survival Following Cytoreductive Nephrectomy for Renal Cell Carcinoma: a Novel 3-Dimensional Volumetric Analysis.

Blute ML Jr, Ziemlewicz TJ, Lang JM, Kyriakopoulos C, Jarrard DF, Downs TM, Grimes M, Shi F, Mann MA, Abel EJ.

Urology. 2017 Feb;100:139-144. doi: 10.1016/j.urology.2016.09.016. Epub 2016 Sep 22.

PMID:
27667156
18.

A biopsy-integrated algorithm for determining Gleason 6 upgrading risk stratifies risk of active surveillance failure in prostate cancer.

Blute ML Jr, Shiau JM, Truong M, Shi F, Abel EJ, Downs TM, Jarrard DF.

World J Urol. 2017 May;35(5):729-735. doi: 10.1007/s00345-016-1933-0. Epub 2016 Sep 15.

PMID:
27631325
19.

A Critical Analysis of Perioperative Outcomes in Morbidly Obese Patients Following Renal Mass Surgery.

Grimes MD, Blute ML Jr, Wittmann TA, Mann MA, Zorn K, Downs TM, Shi F, Jarrard DF, Best SL, Richards KA, Nakada SY, Abel EJ.

Urology. 2016 Oct;96:93-98. doi: 10.1016/j.urology.2016.06.018. Epub 2016 Jun 23.

PMID:
27339026
20.

The evolving role of renal mass biopsy.

Blute ML Jr, Abel EJ.

Ann Transl Med. 2016 Feb;4(4):83. doi: 10.3978/j.issn.2305-5839.2016.01.24. No abstract available.

21.

Management of the Incidental Adrenal Mass.

Thomas AZ, Blute ML Sr, Seitz C, Habra MA, Karam JA.

Eur Urol Focus. 2016 Feb;1(3):223-230. doi: 10.1016/j.euf.2015.12.006. Epub 2016 Feb 3. Review.

PMID:
28723391
22.

Extreme obesity does not predict poor cancer outcomes after surgery for renal cell cancer.

Blute ML Jr, Zorn K, Grimes M, Shi F, Downs TM, Jarrard DF, Best SL, Richards K, Nakada SY, Abel EJ.

BJU Int. 2016 Sep;118(3):399-407. doi: 10.1111/bju.13381. Epub 2015 Dec 22.

23.

Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma.

Cancer Genome Atlas Research Network, Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis C, Wheeler DA, Murray BA, Schmidt L, Vocke CD, Peto M, Al Mamun AA, Shinbrot E, Sethi A, Brooks S, Rathmell WK, Brooks AN, Hoadley KA, Robertson AG, Brooks D, Bowlby R, Sadeghi S, Shen H, Weisenberger DJ, Bootwalla M, Baylin SB, Laird PW, Cherniack AD, Saksena G, Haake S, Li J, Liang H, Lu Y, Mills GB, Akbani R, Leiserson MD, Raphael BJ, Anur P, Bottaro D, Albiges L, Barnabas N, Choueiri TK, Czerniak B, Godwin AK, Hakimi AA, Ho TH, Hsieh J, Ittmann M, Kim WY, Krishnan B, Merino MJ, Mills Shaw KR, Reuter VE, Reznik E, Shelley CS, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Tickoo S, Burnett K, Crain D, Gardner J, Lau K, Mallery D, Morris S, Paulauskis JD, Penny RJ, Shelton C, Shelton WT, Sherman M, Thompson E, Yena P, Avedon MT, Bowen J, Gastier-Foster JM, Gerken M, Leraas KM, Lichtenberg TM, Ramirez NC, Santos T, Wise L, Zmuda E, Demchok JA, Felau I, Hutter CM, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Zhang J, Ayala B, Baboud J, Chudamani S, Liu J, Lolla L, Naresh R, Pihl T, Sun Q, Wan Y, Wu Y, Ally A, Balasundaram M, Balu S, Beroukhim R, Bodenheimer T, Buhay C, Butterfield YS, Carlsen R, Carter SL, Chao H, Chuah E, Clarke A, Covington KR, Dahdouli M, Dewal N, Dhalla N, Doddapaneni HV, Drummond JA, Gabriel SB, Gibbs RA, Guin R, Hale W, Hawes A, Hayes DN, Holt RA, Hoyle AP, Jefferys SR, Jones SJ, Jones CD, Kalra D, Kovar C, Lewis L, Li J, Ma Y, Marra MA, Mayo M, Meng S, Meyerson M, Mieczkowski PA, Moore RA, Morton D, Mose LE, Mungall AJ, Muzny D, Parker JS, Perou CM, Roach J, Schein JE, Schumacher SE, Shi Y, Simons JV, Sipahimalani P, Skelly T, Soloway MG, Sougnez C, Tam A, Tan D, Thiessen N, Veluvolu U, Wang M, Wilkerson MD, Wong T, Wu J, Xi L, Zhou J, Bedford J, Chen F, Fu Y, Gerstein M, Haussler D, Kasaian K, Lai P, Ling S, Radenbaugh A, Van Den Berg D, Weinstein JN, Zhu J, Albert M, Alexopoulou I, Andersen JJ, Auman JT, Bartlett J, Bastacky S, Bergsten J, Blute ML, Boice L, Bollag RJ, Boyd J, Castle E, Chen YB, Cheville JC, Curley E, Davies B, DeVolk A, Dhir R, Dike L, Eckman J, Engel J, Harr J, Hrebinko R, Huang M, Huelsenbeck-Dill L, Iacocca M, Jacobs B, Lobis M, Maranchie JK, McMeekin S, Myers J, Nelson J, Parfitt J, Parwani A, Petrelli N, Rabeno B, Roy S, Salner AL, Slaton J, Stanton M, Thompson RH, Thorne L, Tucker K, Weinberger PM, Winemiller C, Zach LA, Zuna R.

N Engl J Med. 2016 Jan 14;374(2):135-45. doi: 10.1056/NEJMoa1505917. Epub 2015 Nov 4.

24.

Percutaneous biopsy for risk stratification of renal masses.

Blute ML Jr, Drewry A, Abel EJ.

Ther Adv Urol. 2015 Oct;7(5):265-74. doi: 10.1177/1756287215585273. Review.

25.

Maximally Invasive Ablation Versus Minimally Invasive Partial Nephrectomy.

Cheng JS, Blute ML.

Eur Urol Focus. 2015 Aug;1(1):73-74. doi: 10.1016/j.euf.2015.06.006. Epub 2015 Jun 19. No abstract available.

PMID:
28723360
26.

Renin-Angiotensin Inhibitors Decrease Recurrence after Transurethral Resection of Bladder Tumor in Patients with Nonmuscle Invasive Bladder Cancer.

Blute ML Jr, Rushmer TJ, Shi F, Fuller BJ, Abel EJ, Jarrard DF, Downs TM.

J Urol. 2015 Nov;194(5):1214-9. doi: 10.1016/j.juro.2015.05.104. Epub 2015 Jul 11.

PMID:
26173101
27.

Addressing the need for repeat prostate biopsy: new technology and approaches.

Blute ML Jr, Abel EJ, Downs TM, Kelcz F, Jarrard DF.

Nat Rev Urol. 2015 Aug;12(8):435-44. doi: 10.1038/nrurol.2015.159. Epub 2015 Jul 14. Review.

PMID:
26171803
28.

Active surveillance for low-risk prostate cancer: Need for intervention and survival at 10 years.

Preston MA, Feldman AS, Coen JJ, McDougal WS, Smith MR, Paly JJ, Carrasquillo R, Wu CL, Dahl DM, Barrisford GW, Blute ML, Zietman AI.

Urol Oncol. 2015 Sep;33(9):383.e9-16. doi: 10.1016/j.urolonc.2015.04.015. Epub 2015 Jun 6.

PMID:
26059076
29.

Preoperative Anemia as an Independent Prognostic Indicator of Papillary Renal Cell Carcinoma.

Huang J, Feldman AS, Dong L, Cornejo K, Liu Q, Dahl DM, Wu S, Blute ML, Huang Y, Wu CL.

Clin Genitourin Cancer. 2015 Oct;13(5):e353-60. doi: 10.1016/j.clgc.2015.04.014. Epub 2015 May 4.

PMID:
25998556
30.

Emergency cardiopulmonary bypass for massive pulmonary embolism occurring during nephrectomy.

Fikry K, Blute ML, Sundt TM 3rd, McKeen M.

A A Case Rep. 2015 May 1;4(9):117-9. doi: 10.1213/XAA.0000000000000142.

PMID:
25909776
31.

Renal Ischemia and Function After Partial Nephrectomy: A Collaborative Review of the Literature.

Volpe A, Blute ML, Ficarra V, Gill IS, Kutikov A, Porpiglia F, Rogers C, Touijer KA, Van Poppel H, Thompson RH.

Eur Urol. 2015 Jul;68(1):61-74. doi: 10.1016/j.eururo.2015.01.025. Epub 2015 Feb 20. Review.

32.

Frequent disruption of chromodomain helicase DNA-binding protein 8 (CHD8) and functionally associated chromatin regulators in prostate cancer.

Damaschke NA, Yang B, Blute ML Jr, Lin CP, Huang W, Jarrard DF.

Neoplasia. 2014 Dec;16(12):1018-27. doi: 10.1016/j.neo.2014.10.003.

33.

The epigenetics of prostate cancer diagnosis and prognosis: update on clinical applications.

Blute ML Jr, Damaschke NA, Jarrard DF.

Curr Opin Urol. 2015 Jan;25(1):83-8. doi: 10.1097/MOU.0000000000000132. Review.

34.

Potential role for androgen-deprivation therapy and pelvic radiation therapy in node-positive postprostatectomy prostate cancer.

Jarrard DF, Blute ML Jr, Ritter MA.

J Clin Oncol. 2014 Dec 10;32(35):3926-9. doi: 10.1200/JCO.2014.57.8302. Epub 2014 Oct 20. No abstract available.

PMID:
25332250
35.

The role of lymphadenectomy in the management of renal cell carcinoma.

Barrisford GW, Gershman B, Blute ML Sr.

World J Urol. 2014 Jun;32(3):643-9. doi: 10.1007/s00345-014-1294-5. Epub 2014 Apr 11. Review.

PMID:
24723269
36.

Caveat emptor.

Karnes RJ, Joniau S, Blute ML, Van Poppel H.

Eur Urol. 2014 Oct;66(4):673-5; discussion 675-6. doi: 10.1016/j.eururo.2014.03.012. Epub 2014 Mar 18. No abstract available.

PMID:
24674148
37.

Clinical-pathologic stage discrepancy in bladder cancer patients treated with radical cystectomy: results from the national cancer data base.

Gray PJ, Lin CC, Jemal A, Shipley WU, Fedewa SA, Kibel AS, Rosenberg JE, Kamat AM, Virgo KS, Blute ML, Zietman AL, Efstathiou JA.

Int J Radiat Oncol Biol Phys. 2014 Apr 1;88(5):1048-56. doi: 10.1016/j.ijrobp.2014.01.001.

PMID:
24661658
38.

Prognostic significance of indeterminate lung nodules in renal cell carcinoma.

Xu R, Horick N, McGovern FJ, Dahl DM, Feldman AS, Blute ML, Olumi AF, Michaelson MD.

Urol Oncol. 2014 Apr;32(3):355-61. doi: 10.1016/j.urolonc.2013.09.001. Epub 2014 Jan 4.

PMID:
24397994
39.

Factors associated with adoption of robotic surgical technology in US hospitals and relationship to radical prostatectomy procedure volume.

Blute ML, Prestipino AL.

Ann Surg. 2014 Jan;259(1):7-9. doi: 10.1097/SLA.0000000000000390. No abstract available.

PMID:
24326746
40.

Positive surgical margins after radical prostatectomy: does it matter?

Preston MA, Blute ML.

Eur Urol. 2014 Feb;65(2):314-5. doi: 10.1016/j.eururo.2013.08.037. Epub 2013 Aug 26. No abstract available.

PMID:
23993160
41.

Variability of transrectal ultrasound-guided prostate biopsy prophylactic measures.

Hillelsohn JH, Duty B, Blute ML Jr, Okhunov Z, Kashan M, Moldwin R, Ashley RN.

Can J Urol. 2012 Dec;19(6):6573-7.

PMID:
23228295
42.

Image-guided percutaneous renal cryoablation: preoperative risk factors for recurrence and complications.

Blute ML Jr, Okhunov Z, Moreira DM, George AK, Sunday S, Lobko II, Vira MA.

BJU Int. 2013 Apr;111(4 Pt B):E181-5. doi: 10.1111/j.1464-410X.2012.11538.x. Epub 2012 Oct 26.

43.

Renal function after partial nephrectomy: effect of warm ischemia relative to quantity and quality of preserved kidney.

Thompson RH, Lane BR, Lohse CM, Leibovich BC, Fergany A, Frank I, Gill IS, Blute ML, Campbell SC.

Urology. 2012 Feb;79(2):356-60. doi: 10.1016/j.urology.2011.10.031.

PMID:
22310752
44.

Role of cytoreductive nephrectomy in the era of targeted therapy for renal cell carcinoma.

Crispen PL, Blute ML.

Curr Urol Rep. 2012 Feb;13(1):38-46. doi: 10.1007/s11934-011-0225-x. Review.

PMID:
22105577
45.

Intracorporeal neobladder reconstruction: pressure-flow urodyamic studies in cadaveric orthotopic neobladders.

Blute ML Jr, George A, Herati A, Srinivasian A, Vira MA, Kavoussi LR, Richstone L.

BJU Int. 2012 Feb;109(3):434-6. doi: 10.1111/j.1464-410X.2011.10403.x. Epub 2011 Oct 7.

46.

Lymph node dissection in renal cell carcinoma.

Capitanio U, Becker F, Blute ML, Mulders P, Patard JJ, Russo P, Studer UE, Van Poppel H.

Eur Urol. 2011 Dec;60(6):1212-20. doi: 10.1016/j.eururo.2011.09.003. Epub 2011 Sep 13. Review.

PMID:
21940096
47.

Editorial comment.

Blute ML.

Urology. 2011 Sep;78(3):619; author reply 619. doi: 10.1016/j.urology.2011.04.056. No abstract available.

PMID:
21884912
48.

Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer.

Boorjian SA, Karnes RJ, Viterbo R, Rangel LJ, Bergstralh EJ, Horwitz EM, Blute ML, Buyyounouski MK.

Cancer. 2011 Jul 1;117(13):2883-91. doi: 10.1002/cncr.25900. Epub 2011 Jan 10.

49.

Survival after complete surgical resection of multiple metastases from renal cell carcinoma.

Alt AL, Boorjian SA, Lohse CM, Costello BA, Leibovich BC, Blute ML.

Cancer. 2011 Jul 1;117(13):2873-82. doi: 10.1002/cncr.25836. Epub 2011 Jan 10.

50.

Dynamic prediction of metastases after radical prostatectomy for prostate cancer.

Inman BA, Frank I, Boorjian SA, Akornor JW, Karnes RJ, Leibovich BC, Blute ML, Bergstralh EJ.

BJU Int. 2011 Dec;108(11):1762-8. doi: 10.1111/j.1464-410X.2011.10208.x. Epub 2011 May 26.

Supplemental Content

Loading ...
Support Center